References
- Haney EM, Chan BKS, Diem S et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch. Intern. Med.167(12), 1246–1251 (2007).
- Diem S, Blackwell T, Stone KL, Haney EM, Bliziotes MM, Ensrud KE. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures.Arch. Intern. Med.167(12), 1240–1245 (2007).
- Richards JB, Papaioannou A, Adachi JD et al. The impact of selective serotonin reuptake inhibitors on the risk of fracture. Arch. Intern. Med.167(2), 188–194 (2007).
- Michelson D, Stratakis C, Hill L et al. Bone mineral density in women with depression.N. Engl. J. Med.335, 1176–1181 (1996).
- Halbreich U, Rojansky N, Palter S et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med.57, 485–491 (1995).
- Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy.JAMA 282(13), 1264–1269(1999).
- Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T. The association of bone mineral density and depression in an older population. J. Am. Geriatr. Soc.49, 732–736(2001).
- Cizza G, Ravn P, Chrousos G, Gold P. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab.12(5), 198–203(2001).
- Whooley MA, Cauley JA, Zmuda JM, Haney EM, Glynn NW. Depressive symptoms and bone mineral density in older men. J. Geriatr. Psychiatry Neurol.17(2), 88–92(2004).
- Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med.160(21), 3278–3285(2000).
- Rumsfeld JS, Jones PG, Whooley MA et al.Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am. Heart J.150(5), 961–967(2005).
- Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression.Biol. Psychiatry 52, 381–385(2002).
- Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented?Rheum. Dis. Clin. North Am.32, 759–773(2006).
- Bliziotes MM, Eshleman A, Burt-Pichat B et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells.Bone39(6), 1313–1321(2006).
- Bliziotes M, Eshleman A, Zhang X, Wiren K. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake.Bone29(5), 477–486(2001).
- Battaglino R, Fu J, Spate U et al. Serotonin regulates osteoclast differentiation through its transporter.J. Bone Miner. Res.19(9), 1420–1431(2004).
- Westbroek I, Plas AVD, Rooij KD, Klein-Nulend J, Nijweide P. Expression of serotonin receptors in bone.J. Biol. Chem.276(31), 28961–28968(2001).
- Psaty B, Koepsell T, Lin D et al.Assessment and control for confounding by indication in observational studies.J. Am. Geriatr. Soc.47(6), 749–754(1997).
- Walker AM. Confounding by indication. Epidemiology7(4), 335–336(1996).
- Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet370(9590), 851–858(2007).
- Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord.58(1), 19–36(2000).